Fibrosis is a final common pathological end-point of chronic injury in multiple organs, characterized by persistent myofibroblast activation, excessive extracellular matrix (ECM) deposition, and progressive organ dysfunction. Although triggers differ across pulmonary, hepatic, renal, cardiac, and dermal fibrosis, a conserved set of cellular and molecular mechanisms drives disease progression. Translational research has increasingly […]
Fibrosis is a final common pathological end-point of chronic injury in multiple organs, characterized by persistent myofibroblast activation, excessive extracellular matrix (ECM) deposition, and progressive organ dysfunction. Although
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality and morbidity globally. According to the Global Burden of Disease studies, COPD is among the top three causes
Download the full article (PDF) Introduction Antibodies are cornerstone molecules of adaptive immunity and have become central to therapeutic and diagnostic biotechnology. Classical antibodies (e.g., human IgG) comprise two
Download the full article (PDF) Introduction The landscape of targeted cancer therapy has expanded dramatically with the advent of sophisticated small-molecule modalities capable of modulating oncogenic proteins through mechanisms
Download the full article (PDF) Introduction Antibody oligonucleotide conjugates (AOCs) represent an emerging class of biotherapeutics that combine the cell-targeting precision of antibodies with the gene-modulating capabilities of oligonucleotides. Structurally,
Download the full article (PDF) Introduction Immunocytokines, which are fusion proteins combining a cytokine with an antibody or antibody fragment, constitute a rapidly advancing class of targeted immunotherapeutics. They
Download the full article (PDF) Introduction The emergence of chimeric antigen receptor (CAR)-based immunotherapies has revolutionized the treatment of hematologic malignancies. While CAR-T cell therapies dominate the clinical landscape, enthusiasm
Download the full article (PDF) The engineering of chimeric antigen receptor (CAR) T cells has redefined cancer immunotherapy, producing transformative clinical outcomes in hematological malignancies. However, conventional CAR-T therapies
Introduction Cell-based high throughput screening (HTS) platforms have significantly accelerated drug discovery by providing high-content, scalable, and clinically relevant data early in the screening pipeline. Cell-based assays have become indispensable
The landscape of cancer immunotherapy is rapidly evolving with the emergence of several cutting-edge modalities. Some examples include genetically engineered chimeric antigen receptor (CAR) immune cell subsets, neoantigen vaccines
